Whats New

APS - encapsulation

The Company's 'APS' encapsulation system (used for taste masking,  to control nutrient and drug delivery and to encapsulate cells such as bacteria) has proved to be an effective system for the encapsulation and stabilisation of probiotic bacteria. Long shelf life has been achieved with the technology both in vitro and within formulated food products. Further trials are being conducted and publications are being prepared.

Commercial trials being conducted with relevant partners.

BLD - oral flash melt

The Glycologic Limited 'BLD' technology is gradually being licensed to more companies interested in oral 'melt' delivery of drugs. A key focus at this time is hay fever, migraine and heartburn/ gastric reflux.

Current trials with partners are progressing very well. Applications using the material as a gelatine replacement in broader clinical/pharmaceutical applications are also being developed.

SERS - hypoglycaemia

Recent trials on the Glycologic Limited 'SERS' technology - to treat hypoglycaemia in type 1 diabetics -has proven to be very successful. These data complement the data generated for healthy individuals using the technology for sports applications and for forms of liver disease such as glycogen storage disease (GSD) and general liver damage. The technology restricts the number and duration of hypoglycaemic events.

Clinicals Trials:

GSD - Phase 3 Complete, product goes live 2008

Type 1 Diabetes - Phase 1 Complete, very positive outcome

Prebiotic

Work is progressing well on the technology for gut health, topical skin care and related health applications (especially vaginal health). Early indications are that the technology provides an effective therapy for Candida albicans infections and other topical condictions of the skin.

For gastric health applications, both animal and human trials have been very successful. In broad terms, the material increases the gut friendly bacteria in the colon and depresses the growth of the pathogenic organisms.

Clinicals Trials:

Colonic Health: Phase 1-3 Complete, marketing trials initiated in one territory

Vaginal Health: Pre-clinical, Phase 1 to begin

GRS - gastric retention

The applications for this technology are being pursued through separate avenues for (i) satiety, (ii) gastric delivery and GORD (GERD) therapy.

Clinicals Trials:

Satiety: Phase 1 has proven efficacy for satiety applications

Gastric Retention: Phase 1 trials planned

GORD: Phase 1 trials planned

Wound Management

New wound matrix technology proving very effective in-vitro. Licensing arrangements being consolidated.

Diagnostic Kits

Clinical diagnostic kits utilising the Glycologic Limited technology have entered trials in a number of hospitals since July 2008. In addition, other kits designed for specific clients and directed towards detecting carbohydrate derivatives in a number of food and pharmaceutical systems are going live for sales across the world. A press release is intended for Autumn 2008.